These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7366673)

  • 1. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.
    Shepherd J; Packard CJ; Bicker S; Lawrie TD; Morgan HG
    N Engl J Med; 1980 May; 302(22):1219-22. PubMed ID: 7366673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
    N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined drug therapy for familial hypercholesterolemia.
    Packard CJ; Stewart JM; Morgan HG; Lorimer AR; Shepherd J
    Artery; 1980; 7(4):281-9. PubMed ID: 7213018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
    Pappu AS; Illingworth DR
    J Lab Clin Med; 1989 Nov; 114(5):554-62. PubMed ID: 2809398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans.
    Lind S; Rudling M; Ericsson S; Olivecrona H; Eriksson M; Borgström B; Eggertsen G; Berglund L; Angelin B
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):349-56. PubMed ID: 14656733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.
    Rader DJ; Mann WA; Cain W; Kraft HG; Usher D; Zech LA; Hoeg JM; Davignon J; Lupien P; Grossman M
    J Clin Invest; 1995 Mar; 95(3):1403-8. PubMed ID: 7883987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of partial ileal bypass over cholestyramine reducing cholesterol in familial hypercholesterolaemia.
    Spengel FA; Jadhav A; Duffield RG; Wood CB; Thompson GR
    Lancet; 1981 Oct; 2(8250):768-70. PubMed ID: 6116902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients.
    Malmendier CL; Delcroix C; Lontie JF
    Clin Chim Acta; 1987 Jan; 162(2):221-7. PubMed ID: 3829426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of familial hypercholesterolemia in childhood: diet and cholestyramine resin for 24 to 36 months.
    Glueck CJ; Tsang RC; Fallat RW; Mellies M
    Pediatrics; 1977 Mar; 59(3):433-41. PubMed ID: 840563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.
    Kane JP; Malloy MJ; Tun P; Phillips NR; Freedman DD; Williams ML; Rowe JS; Havel RJ
    N Engl J Med; 1981 Jan; 304(5):251-8. PubMed ID: 7003391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of LDL receptors and response to lovastatin therapy in familial homozygotic hypercholesterolemia].
    Ausina Gómez A; Gilsanz Peral A; Montero Brens C; Dalmau Serra J
    An Esp Pediatr; 1991 Nov; 35(5):327-31. PubMed ID: 1785747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia.
    Thompson GR; Ford J; Jenkinson M; Trayner I
    Q J Med; 1986 Aug; 60(232):803-11. PubMed ID: 3640503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemic subjects.
    Hoeg JM; Demosky SJ; Schaefer EJ; Starzl TE; Brewer HB
    J Clin Invest; 1984 Feb; 73(2):429-36. PubMed ID: 6321555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Catabolism of low-density lipoproteins via receptors and its regulation].
    Mazière JC; Mazière C; Gardette J; Polonovski J
    Ann Biol Clin (Paris); 1986; 44(5):545-50. PubMed ID: 3544977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of low-dose cholestyramine in long-term therapy of hypercholesterolemia].
    Cattin L; Da Col PG; Fonda M; Mazzone C; Pertot P
    G Clin Med; 1990 Feb; 71(2):99-104. PubMed ID: 2347462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-mediated low density lipoprotein catabolism in man.
    Shepherd J; Bicker S; Lorimer AR; Packard CJ
    J Lipid Res; 1979 Nov; 20(8):999-1006. PubMed ID: 230269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.